Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03297125 · ClinicalTrials.gov registry record
Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI
A clinical trial of Glioblastoma, sponsored by Medical College of Wisconsin.
- Active
- Registry status
- 60
- Enrollment target
- 1
- Study location
NCT03297125 is a study of Glioblastoma that is active but no longer recruiting, run by Medical College of Wisconsin. The registered enrollment target is 60 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (45% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03297125, a study of Glioblastoma, is active but no longer recruiting, sponsored by Medical College of Wisconsin.
- ACTIVE NOT RECRUITING
- Registry status
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this prospective, nonrandomized controlled phase IV study is to compare standard and advanced MRI for their ability to predict response to Optune therapy.
Conditions Studied
Interventions
- DEVICE Standard Magnetic Resonance Imaging (MRI)
- DEVICE Advanced MRI.
Study Locations (1)
Wisconsin
- Froedtert Hospital & Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2017-12-01 |
| Est. Completion | 2026-01-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03297125
The ClinicalTrials.gov registry entry for NCT03297125 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (45% lower). The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glioblastoma appearing as the primary indexed condition, and to 2 interventions - of which Standard Magnetic Resonance Imaging (MRI) is the first listed.
NCT03297125 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT03297125 about?
NCT03297125 is a clinical study titled "Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI". The purpose of this prospective, nonrandomized controlled phase IV study is to compare standard and advanced MRI for their ability to predict response to Optune therapy.
What is the current status of trial NCT03297125?
This trial is currently active not recruiting. The enrollment target is 60 participants. The study started on 2017-12-01. Estimated completion is 2026-01-01.
What conditions does trial NCT03297125 study?
This clinical trial studies the following conditions: Glioblastoma.
What interventions are being tested in trial NCT03297125?
The interventions under investigation include: Standard Magnetic Resonance Imaging (MRI) (DEVICE), Advanced MRI. (DEVICE).
Who is sponsoring clinical trial NCT03297125?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03297125 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NovoTTF Treatment Signatures in Glioblastoma Patients At Autopsy
RECRUITING
-
Glioblastoma Remote Monitoring and Care - Research Protocol
RECRUITING · NA
-
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
RECRUITING · Phase 2
-
Venous Thromboembolism Prevention in Outpatients With Glioma
RECRUITING · Phase 2
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.